- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06477289
Perifer arteriel tonometri og neurokognition ved seglcellesygdom
Denne undersøgelse vil undersøge søvnforstyrret vejrtrækning og søvnkvalitet hos deltagere (i alderen 12-18) diagnosticeret med seglcellesygdom af enhver genotype. Vi vil bruge fjern perifer arteriel tonometri (PAT) og spørgeskemaer til at evaluere problemer med søvn. PAT-vurderinger vil ske eksternt i deltagernes hjem.
Neurokognitive, adfærdsmæssige og neuroimaging-evalueringer vil finde sted samme dag som et rutinemæssigt klinikbesøg.
Primært mål:
Evaluer forholdet mellem natlig oxyhæmoglobinmætning (SpO2) og neurokognitiv funktion (arbejdshukommelse og verbal forståelse) hos børn (i alderen 12-18) diagnosticeret med seglcellesygdom, kontrollerende for alder, genotype og social sårbarhed.
Sekundært mål:
Vurder forskelle i integritet af hvid substans, tavse hjerneinfarkter, neuroinflammation og funktionel forbindelse blandt børn (i alderen 12-18) diagnosticeret med seglcellesygdom med og uden søvnforstyrret vejrtrækning efter alderskontrol.
Vurder forskelle i selv- og omsorgsgiver-rapporteret humør og smertesværhedsgrad blandt børn (i alderen 12-18) diagnosticeret med seglcellesygdom med og uden søvnforstyrret vejrtrækning efter alderskontrol.
Udforskende mål:
Udforsk forholdet mellem natlig oxyhæmoglobinmætning (SpO2) og neurokognitiv funktion (opmærksomhed, behandlingshastighed, verbal hukommelse, visuel hukommelse, motorisk behændighed) hos børn (i alderen 12-18) diagnosticeret med seglcellesygdom, der kontrollerer alder, genotype og social sårbarhed .
Vurder gennemførligheden af et ultraportabelt ringoximeter (BodimetricsCircul+ Ring) hos børn (i alderen 12-18) diagnosticeret med seglcellesygdom.
Vurder overensstemmelsen mellem Circul+Ringen og WatchPAT hos børn (i alderen 12-18) diagnosticeret med seglcellesygdom.
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiekontakt
- Navn: Andrew Heitzer, PhD
- Telefonnummer: 888-226-4343
- E-mail: referralinfo@stjude.org
Undersøgelse Kontakt Backup
- Navn: Stephanie Guthrie, RN, BSN
- Telefonnummer: 888-226-4343
- E-mail: referralinfo@stjude.org
Studiesteder
-
-
Tennessee
-
Memphis, Tennessee, Forenede Stater, 38105
- Rekruttering
- St. Jude Children's Research Hospital
-
Kontakt:
- Andrew Heitzer, PhD
- Telefonnummer: 888-226-4343
- E-mail: referralinfo@stjude.org
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
Tager imod sunde frivillige
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inklusionskriterier:
- Diagnosticeret med seglcellesygdom af enhver genotype
- Deltager i Sickle Cell Clinical Research and Intervention Program
- Mellem 12-18 år på indskrivningstidspunktet
- Engelsk er det primære sprog
- Adgang til en smartphone eller tablet til brug med Circul+ Ring
Ekskluderingskriterier:
- Historien om et intellektuelt handicap
- Historie om en traumatisk hjerneskade eller anfaldsforstyrrelse
- Historien om et slagtilfælde
- Gennemgår potentiel helbredende behandling for SCD (stamcelletransplantation eller genterapi)
- I øjeblikket ordineret en intervention for en søvnforstyrrelse
- Forskningsdeltagers eller juridiske værge/repræsentants manglende evne eller vilje til at give skriftligt informeret samtykke.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Evaluate the relationship between nocturnal oxyhemoglobin saturation (SpO2) and neurocognitive functioning (working memory and verbal comprehension) in individuals (ages 12-25) diagnosed with sickle cell disease.
Tidsramme: Baseline remote sleep assessment over 3 days followed by in-clinic assessment.
|
A linear regression model will be used to assess the relationship between SpO2 and neurocognitive functioning after adjusting for age, genotype, and social vulnerability.
|
Baseline remote sleep assessment over 3 days followed by in-clinic assessment.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Assess differences in white matter integrity among individuals (ages 12-25) diagnosed with sickle cell disease with and without sleep disordered breathing.
Tidsramme: Baseline remote sleep assessment over 3 days followed by in-clinic assessment.
|
This study will measure resting-state BOLD signal in SCD patients after assessing nocturnal oxyhemoglobin saturation.
The primary endpoint is the whole brain BOLD response and functional connectivity among brain regions within the default mode, fronto-parietal, executive control, salience, sensorimotor, and other resting state networks.
Then we will compare differences in white matter integrity based on the structural connectivity connectome for the working memory network, silent cerebral infarcts, neuroinflammation, and functional connectivity among individuals with and without sleep disordered breathing.
|
Baseline remote sleep assessment over 3 days followed by in-clinic assessment.
|
|
Assess differences in silent cerebral infarcts among individuals (ages 12-25) diagnosed with sickle cell disease with and without sleep disordered breathing.
Tidsramme: Baseline remote sleep assessment over 3 days followed by in-clinic assessment.
|
This study will measure resting-state BOLD signal in SCD patients after assessing nocturnal oxyhemoglobin saturation.
The primary endpoint is the whole brain BOLD response and functional connectivity among brain regions within the default mode, fronto-parietal, executive control, salience, sensorimotor, and other resting state networks.
Then we will compare differences in white matter integrity based on the structural connectivity connectome for the working memory network, silent cerebral infarcts, neuroinflammation, and functional connectivity among individuals with and without sleep disordered breathing.
|
Baseline remote sleep assessment over 3 days followed by in-clinic assessment.
|
|
Assess differences in self- and caregiver-reported mood and pain severity among individuals (ages 12-25) diagnosed with sickle cell disease with and without sleep disordered breathing after controlling for age.
Tidsramme: Baseline remote sleep assessment over 3 days followed by in-clinic assessment.
|
The general linear regression model is then used to assess the relationship of functional connectivity and to assess the relationship of self- and caregiver-reported mood and pain severity with sleep disordered breathing with controlling for age in the model.
As a secondary analysis, we will also associate continuous obstructive and central AHI with functional connectivity and self- and caregiver-reported mood and pain severity using linear regression model with adjusting for age.
|
Baseline remote sleep assessment over 3 days followed by in-clinic assessment.
|
|
Assess differences in neuroinflammation, among individuals (ages 12-25) diagnosed with sickle cell disease with and without sleep disordered breathing.
Tidsramme: Baseline remote sleep assessment over 3 days followed by in-clinic assessment.
|
This study will measure resting-state BOLD signal in SCD patients after assessing nocturnal oxyhemoglobin saturation.
The primary endpoint is the whole brain BOLD response and functional connectivity among brain regions within the default mode, fronto-parietal, executive control, salience, sensorimotor, and other resting state networks.
Then we will compare differences in white matter integrity based on the structural connectivity connectome for the working memory network, silent cerebral infarcts, neuroinflammation, and functional connectivity among individuals with and without sleep disordered breathing.
|
Baseline remote sleep assessment over 3 days followed by in-clinic assessment.
|
|
Assess differences in functional connectivity among individuals (ages 12-25) diagnosed with sickle cell disease with and without sleep disordered breathing after controlling for age.
Tidsramme: Baseline remote sleep assessment over 3 days followed by in-clinic assessment.
|
This study will measure resting-state BOLD signal in SCD patients after assessing nocturnal oxyhemoglobin saturation.
The primary endpoint is the whole brain BOLD response and functional connectivity among brain regions within the default mode, fronto-parietal, executive control, salience, sensorimotor, and other resting state networks.
Then we will compare differences in white matter integrity based on the structural connectivity connectome for the working memory network, silent cerebral infarcts, neuroinflammation, and functional connectivity among individuals with and without sleep disordered breathing.
|
Baseline remote sleep assessment over 3 days followed by in-clinic assessment.
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Explore the association among nocturnal SpO2 and neurocognitive function (attention, processing speed, verbal/visual memory, motor dexterity) in individuals aged 12-25 years with sickle cell disease adjusting for age, genotype, and social vulnerability.
Tidsramme: Baseline remote sleep assessment over 3 days followed by in-clinic assessment.
|
A linear regression model will be used to assess the relationship between SpO2 and neurocognitive functioning after adjusting for age, genotype, and social vulnerability
|
Baseline remote sleep assessment over 3 days followed by in-clinic assessment.
|
|
Assess the feasibility of an ultraportable ring oximeter (BodimetricsCircul+ Ring) in individuals (ages 12-25) diagnosed with sickle cell disease.
Tidsramme: Baseline remote sleep assessment over 3 days followed by in-clinic assessment.
|
Feasibility of the Circul+Ring equipment will be defined as more than 50% of participants wearing Circul+Ring for at least one night's sleep.
There is no power calculation needed for this feasibility objective.
However, 55 participants give 92% power to detect a 20% difference at an assumed 70% of participants who will wear the ring for at least one night's sleep, with a significance level of 0.05 based on a one-sided test.
The number of hours worn for the WatchPAT and Circul+Ring will be compared using Wilcoxon rank sum test.
Descriptive statistics will be used to summarize the two-question survey.
|
Baseline remote sleep assessment over 3 days followed by in-clinic assessment.
|
|
Assess the concordance between the Circul+Ring with the WatchPAT in individuals (ages 12-25) diagnosed with sickle cell disease.
Tidsramme: Baseline remote sleep assessment over 3 days followed by in-clinic assessment.
|
To evaluate concordance, the nocturnal SpO2 obtained using the WatchPAT and a Circul+ Ring will be plotted against each other, and Pearson/Spearman correlations will be used to examine their relationship.
The Bland-Altman method will be used to investigate the variability between the two measurements using the WatchPAT and Circul+ Ring.
Lin's concordance correlation coefficient will be determined to demonstrate the level of agreement.
|
Baseline remote sleep assessment over 3 days followed by in-clinic assessment.
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Andrew Heitzer, PhD, St. Jude Children's Research Hospital
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- PATSCANS
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .